Deepali Malhotra

Title: Deepali Malhotra: Innovator in Major Histocompatibility Class II Molecules

Introduction

Deepali Malhotra is a prominent inventor based in Minneapolis, MN (US). She has made significant contributions to the field of immunology through her innovative work on major histocompatibility class II (MHCII) molecules. Her research focuses on enhancing the affinity of these molecules for CD4 co-receptors, which has important implications for immunological research and therapies.

Latest Patents

Deepali holds a patent for "Co-receptor affinity enhanced major histocompatibility class II molecules." This patent describes variant MHCII beta chains, as well as heterodimers and multimers that include MHCII alpha chains and the variant MHCII beta chains. The disclosed inventions also encompass nucleic acids, expression cassettes, and expression vectors that encode the MHCII beta chains. The heterodimers and multimers developed by Deepali exhibit a higher affinity for CD4 co-receptors compared to wild type MHCII beta chains, making them advantageous for phenotyping or activating CD4 T cells.

Career Highlights

Deepali is affiliated with the University of Minnesota, where she conducts her research and contributes to the academic community. Her work has garnered attention for its potential applications in immunotherapy and vaccine development.

Collaborations

Deepali collaborates with notable colleagues, including Marc Kevin Jenkins and Thamotharampillai Dileepan. These collaborations enhance her research efforts and contribute to advancements in the field.

Conclusion

Deepali Malhotra is a trailblazer in the field of immunology, with her innovative patent on MHCII molecules paving the way for future research and applications. Her contributions are vital to the ongoing exploration of immune responses and therapeutic strategies.